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Epigenome-wide association study of
kidney function identifies trans-ethnic and
ethnic-specific loci
Charles E. Breeze1,2,3* , Anna Batorsky4, Mi Kyeong Lee5, Mindy D. Szeto6, Xiaoguang Xu7, Daniel L. McCartney8,
Rong Jiang9, Amit Patki10, Holly J. Kramer11,12, James M. Eales7, Laura Raffield13, Leslie Lange6, Ethan Lange6,
Peter Durda14, Yongmei Liu15, Russ P. Tracy14,16, David Van Den Berg17, NHLBI Trans-Omics for Precision Medicine
(TOPMed) Consortium, TOPMed MESA Multi-Omics Working Group, Kathryn L. Evans8, William E. Kraus15,18,
Svati Shah15,18, Hermant K. Tiwari10, Lifang Hou19,20, Eric A. Whitsel21,22, Xiao Jiang7, Fadi J. Charchar23,24,25,
Andrea A. Baccarelli26, Stephen S. Rich27, Andrew P. Morris28, Marguerite R. Irvin29, Donna K. Arnett30,
Elizabeth R. Hauser15,31, Jerome I. Rotter32, Adolfo Correa33, Caroline Hayward34, Steve Horvath35,36,
Riccardo E. Marioni8, Maciej Tomaszewski7,37, Stephan Beck2, Sonja I. Berndt1, Stephanie J. London5,
Josyf C. Mychaleckyj27 and Nora Franceschini21*
Abstract
Background: DNA methylation (DNAm) is associated with gene regulation and estimated glomerular filtration rate
(eGFR), a measure of kidney function. Decreased eGFR is more common among US Hispanics and African
Americans. The causes for this are poorly understood. We aimed to identify trans-ethnic and ethnic-specific
differentially methylated positions (DMPs) associated with eGFR using an agnostic, genome-wide approach.
Methods: The study included up to 5428 participants from multi-ethnic studies for discovery and 8109 participants
for replication. We tested the associations between whole blood DNAm and eGFR using beta values from Illumina
450K or EPIC arrays. Ethnicity-stratified analyses were performed using linear mixed models adjusting for age, sex,
smoking, and study-specific and technical variables. Summary results were meta-analyzed within and across
ethnicities. Findings were assessed using integrative epigenomics methods and pathway analyses.
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Results: We identified 93 DMPs associated with eGFR at an FDR of 0.05 and replicated 13 and 1 DMPs across
independent samples in trans-ethnic and African American meta-analyses, respectively. The study also validated 6
previously published DMPs. Identified DMPs showed significant overlap enrichment with DNase I hypersensitive
sites in kidney tissue, sites associated with the expression of proximal genes, and transcription factor motifs and
pathways associated with kidney tissue and kidney development.
Conclusions: We uncovered trans-ethnic and ethnic-specific DMPs associated with eGFR, including DMPs enriched
in regulatory elements in kidney tissue and pathways related to kidney development. These findings shed light on
epigenetic mechanisms associated with kidney function, bridging the gap between population-specific eGFR-
associated DNAm and tissue-specific regulatory context.
Keywords: Epigenetic, Kidney function, Gene regulation, Kidney development, DNA methylation
Background
The kidney has a central role in body homeostasis
through the regulation of blood pressure, fluid, and elec-
trolytes and by removing endogenous and exogenous
toxins. Reduced kidney function measured using esti-
mated glomerular filtration rate (eGFR) defines chronic
kidney disease (CKD). CKD affects 14.5% of the adult
US population and is a leading cause of death and dis-
ability [1, 2]. CKD has a high burden among non-
European US ethnic groups, but mechanisms for this
health disparity are poorly understood [3]. A better un-
derstanding of the mechanisms influencing kidney func-
tion may provide insights into CKD occurrence and risk.
Complex interactions between genetic, lifestyle, and
environmental exposures likely contribute to the ob-
served eGFR variation across populations. DNA se-
quence variation accounts for 7.6% of the estimated
heritability of eGFR in trans-ethnic genome-wide associ-
ation studies (GWAS) [4]. Epigenetic modifications of
the genome such as DNA methylation (DNAm) are her-
itable and contribute to gene regulation. DNAm consists
of the addition of a methyl group to cytosines, typically
at cytosine-guanine dinucleotides (CpG sites). DNAm is
influenced by lifetime exposures and may provide clues
on ethnic-specific differences influencing eGFR. Differ-
ential DNAm at CpG sites can be studied using microar-
rays with reasonable genome-wide coverage through
epigenome-wide association studies (EWAS) [5, 6].
Recent EWAS in whole blood have identified differen-
tially methylated positions (DMPs) associated with blood
pressure and eGFR, and disease states such as CKD and
rapid decline in eGFR [7–11]. Early studies had modest
sample sizes (40 to 407 individuals) or were limited to a
single ethnic group [7–9]. A large EWAS performed sep-
arate discovery analyses within the Atherosclerosis Risk
in Communities (ARIC, 2264 African Americans) and
the Framingham Heart Study (FHS, 2395 white partici-
pants) followed by cross-replication of findings [11]. The
study identified 19 DMPs for eGFR or CKD. Overall,
these studies support a role for DNAm in CKD-related
traits. However, previous studies did not account for im-
portant potential confounders such as smoking status
and cumulative exposure in the discovery group, which
have widespread effects on DNAm patterns [12] and are
risk factors for CKD, nor did they assess DNAm at CpG
sites across multiple ethnic groups during discovery.
The main aim of this study is to identify DNAm pat-
terns associated with eGFR in multi-ethnic studies using
data from European/European American (EA), African
American (AA), and Hispanic/Latino (H/L) participants.
We performed both trans-ethnic and ethnic-specific
EWAS using whole blood-based Illumina DNAm data
assayed in participants of the Women’s Health Initiative
(WHI), the Multi-Ethnic Atherosclerosis Study (MESA),
and the Jackson Heart Study (JHS). We replicated our
findings in the HyperGEN, Generation Scotland, and
CATHGEN studies, in addition to analyzing results via
look-ups in a published study [11]. We identified DMPs
associated with eGFR in trans-ethnic and ethnic-specific
analyses, and provided supporting evidence for the con-
tribution of identified DMPs to kidney function and de-
velopment using in silico approaches and human kidney
tissue-specific data.
Methods
Study design and populations
Our study design included a discovery step comprising
three population-based studies (WHI, MESA, and JHS)
and three replication studies (HyperGEN, Generation
Scotland, and CATHGEN) (Additional file 1: Fig. S1).
WHI is a study of postmenopausal women (aged 50–79
years), comprising 161,808 women recruited from 40 US
clinical centers who participated in an observational
study or in clinical trials during 1993–1998 as previously
described [13–16]. MESA is a multi-ethnic study of sub-
clinical cardiovascular disease and risk factors for cardio-
vascular disease [17], consisting of 6814 asymptomatic
men and women aged 45–84 (38% EA, 28% AA, 22% H/
L, and 12% Asian) recruited from six field centers across
the USA and examined in 2000–2002, followed by four
Breeze et al. Genome Medicine           (2021) 13:74 Page 2 of 16
subsequent examination periods. JHS is a study of car-
diovascular disease and its risk factors in AA, comprising
5306 African Americans aged 21 to 94 years recruited
from the Jackson, MS, metropolitan area from 2000 to
2004, with four follow-up exams [18]. HyperGEN is a
family-based study with a sib-pair design. Hypertensive
African American sibships were recruited from Forsyth
County, NC, and from the community-at-large in Bir-
mingham, AL, from 1995 to 2000 [19]. Generation
Scotland is a family-based and population-based study
consisting of 23,690 European participants recruited via
general medical practices across Scotland between the
years 2006 and 2011 [20]. CATHGEN is a biorepository
of clinical samples from a prospectively collected clinical
cohort of individuals undergoing cardiac catheterization
at Duke University [21]. Both discovery and replication
included multi-ethnic studies. Study descriptions are
shown in Additional file 2: Supplementary Methods.
Phenotypes
Serum creatinine-based eGFR was estimated using the
Chronic Kidney Disease Epidemiology equation which
includes age, sex, and a constant for AA [22].
Epigenetic data and quality control
Briefly, preprocessing included removal of probes with de-
tection p values > 0.01 in > 10% of samples and samples
with detection p values > 0.01 in > 1% of probes. Beta values
were normalized using beta-mixture quantile (BMIQ)
normalization method (WHI-BAA and WHI-EMPC) [23],
the normal-exponential out-of-band (NOOB) preprocess-
ing method (JHS, MESA, CATHGEN) [24], Subset Quan-
tile Normalization (SQN) (CATHGEN) [25], or dasen
(Generation Scotland) [26]. Batch effect correction was per-
formed using ComBat [27] or adjusting batch as a covariate.
CpGs overlapping with the list of potentially polymorphic
sites in the relevant ethnic group and cross-reactive probes
were removed [28]. Cell proportions were estimated using
the reference-based Houseman method for whole blood
[29]. To adjust for population structure, principal compo-
nents (PCs) or ethnic-informative markers were obtained
from the genome-wide genotype data available using stand-
ard methods [30]. DNAm sites were annotated to include
chromosome, position, UCSC gene names, relationship to
CpG islands, location in gene enhancer regions, and DNase
I hypersensitive sites (DHSs) using Illumina’s annotation
file [31]. Detailed methods for MESA, which have not been
previously published, are included in Additional file 2: Sup-
plementary Methods.
EWAS
Methylation betas were used as predictors for eGFR in
ethnic-stratified analyses, adjusting for age, sex, smoking
history (current, past, and no smoking, and pack-years),
4 to 10 principal components, cell type composition, and
study-specific covariates. DMPs were modeled by fitting
robust linear models (or linear mixed models in JHS to
account for family relationships) and performing robust
standard error calculations via the 'sandwich' package.
These analyses were performed using R version 3.5.3.
Because of the small samples within each ethnicity in
MESA, we fitted linear models in that study without ro-
bust estimation. EWAS results were meta-analyzed
across all samples and within each ethnicity using fixed-
effect inverse-variance weighted methods implemented
in METAL. We required a minimum of two studies for
meta-analyses. We used an FDR < 0.05 (Benjamini-
Hochberg).
EWAS analyses were subsequently performed in
HyperGEN (AA), Generation Scotland (EA), and CATH
GEN (AA and EA) using the same statistical protocols
as in discovery analyses. For trans-ethnic replication, we
combined all the replication samples and used a
Bonferroni-adjusted p-value cutoff for the 78 tests that
were performed (p = 6.4E−04). We also considered if the
direction of effects between discovery and replication
samples was concordant. For ethnic-specific replication,
we used EA replication samples for EA or H/L discovery
meta-analyses, while for AA replication, we used AA
replication samples, a Bonferroni-corrected p < 2.1E−03,
and consistency in direction of effects. We also
attempted to replicate DMPs from a published study
[11]. This published study used eGFR instead of DMPs
as a predictor in models and therefore the estimates
were not comparable to our study.
In silico annotation using eFORGE and eFORGE-TF, and
pathway analyses
We performed functional overlap analysis of DMPs with
eFORGE version 2.0, analyzing the default top 1000
probes from EA, AA, H/L, and all-ethnic probe sets for
overlap enrichment across DNase I hotspots from the
Roadmap Epigenomics Consortium [32, 33]. To ascer-
tain whether the observed enrichment was robust and
associated with top probe sets below the EWAS signifi-
cance threshold, we applied additional eFORGE analyses
across the 5 top EA CpG sets (comprising CpGs 1–
1000, 1000–2000, 2000–3000, 3000–4000, 4000–5000,
ordered by p-value), to detect overlap enrichment across
DNase I hotspots from the Roadmap Epigenomics Con-
sortium [32, 33]. We thus performed integrative epige-
nomics analyses on data from the Roadmap
Epigenomics consortium [34] using the eFORGE frame-
work (https://eforge.altiusinstitute.org/) [32, 33]. To fur-
ther understand eFORGE enrichment results, we
performed TF motif analysis on the probes underlying
eFORGE tissue-specific enrichment signal for kidney.
We used the eFORGE-TF module, seeking to uncover
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the main TF motifs associated with our DNase I hotspot
enrichment for top sites [33]. We used PANTHER ana-
lysis via the AmiGO framework to uncover pathways as-
sociated with the identified TF motifs [35].
meQTL data in the whole blood
We used publicly available data from the biobank-based
integrative omics study (BIOS) QTL database [36, 37]
and cis-meQTL data from the FHS (n = 4170 partici-
pants, 450K DNAm panel, 1000G imputed data, defined
within 2-Mb window) [38]. We also used meQTL data
from mQTLdb [39].
meQTL in normal kidney tissue
We analyzed a total of 211 individuals with matching
kidney genome-epigenome information from TRAN
Scriptome of renaL humAn TissuE Study (TRANSLAT
E), an extension of the TRANSLATE study (TRANSLAT
E-T), Renal gEne expreSsion and PredispOsition to car-
diovascular and kidNey Disease (RESPOND), and mo-
lecular analysis of mechanisms regulating gene
expression in post-ischemic injury to renal allograft
(REPAIR) (n = 192), in addition to normal samples with
available genotype and kidney DNAm profiles from the
National Institutes of Health (NIH) Tissue Cancer Gen-
ome Atlas (TCGA) (n = 19) [40–43]. Kidney tissue sam-
ples from TRANSLATE, RESPOND, and TCGA were
taken from the healthy, unaffected by cancer part of the
organ after elective nephrectomies, and renal specimens
in TRANSLATE-T and REPAIR studies were collected
as pre-implantation biopsies from deceased donors’ kid-
neys before transplantation [40, 42, 43]. Information on
local recruitment teams, genotyping, and DNAm
methods are included in Additional file 2: Supplemen-
tary Methods. In total, 374,826 CpG sites were available
for further analyses after quality control filters. For post-
EWAS DMP analysis, we conducted kidney cis-meQTL
analysis on 62 DMPs (out of 374,826) from the study.
For GWAS SNP analysis, we conducted kidney cis-
meQTL analysis on a set of published eGFR GWAS
SNPs [44]. The cis-meQTL analysis was conducted on
195 kidney DNA samples that passed all quality control
criteria. For analysis, we used the FastQTL pipeline [45].
We used normalized M-values and genotype information
for all genotyped and imputed variants passing the qual-
ity control filters under an additive mode of inheritance.
Regression models included age, sex, genotyping array,
source of tissue indicator (nephrectomy/kidney biopsy),
the top three PCs derived from genotyped autosomal
variants (genotype PCs), and six PCs derived from
methylation array control probes (methylation PCs). The
FastQTL cis-region was defined as ±1Mb from each
tested CpG/SNP position. For EWAS DMP blood-
kidney meQTL comparison analysis, we compared
DMP+kidney meQTL CpGs to blood meQTL CpGs
from mQTLdb and calculated the percentage of overlap
for data from both sources.
eFORGE analysis for kidney meQTL CpGs
Standard eFORGE analyses were performed using de-
fault settings. For kidney meQTL CpGs, we analyzed
eGFR SNPs overlapping kidney DNase I hotspots (top
category from https://forge2.altiusinstitute.org/files/
0x454A546E8E9C11EA8198793F5BFE3F98/index.html).
We searched for these SNPs in the kidney meQTL file,
obtaining preliminary associated meQTL CpGs (nominal
p-value < 0.05) and preliminary non-associated meQTL
CpGs (nominal p-value > 0.95), for the same set of SNPs.
Standard eFORGE analyses were performed on both of
these sets.
Results
Overview of EWAS results
The study design is shown in Fig. 1 and Additional file 1:
Fig. S1. Discovery EWAS meta-analyses included up to
5428 individuals, with 2879 AA, 1737 EA, and 812 H/L
participants (Additional file 3: Table S1). Quality control
of DNAm data and protocol analyses for each study are
shown in Additional file 3: Table S2. We performed ana-
lyses within each study and ethnic group using standard
statistical protocols followed by meta-analyses of the
overall samples and within each ethnicity. The quantile-
quantile and Manhattan plots for meta-analyses are
shown in Additional file 1: Fig. S2. Lambdas for meta-
analyses were 0.987 (AA), 1.001 (EA), 1.065 (H/L), and
1.194 (trans-ethnic meta-analysis). Across our discovery
analyses, we identified a total of 93 DMPs associated
with eGFR at an FDR of 0.05. Of these, 78 DMPs were
identified in trans-ethnic meta-analyses, 23 DMPs in the
meta-analysis of AA, 5 in the meta-analysis of H/L, and
5 in the meta-analysis of EA, with some overlap in DMP
findings between trans-ethnic and ethnic-specific results.
Indeed, most of the DMPs identified in trans-ethnic
analyses were also present in one or more ethnic groups
(Fig. 1a). However, the overlap between DMPs of AA
and EA was small. Trans-ethnic replication included up
to 8109 participants from three studies (Generation
Scotland, CATHGEN, and HyperGEN), composed of
participants of EA and AA (9% of replication samples)
(Additional file 1: Fig. S1) [11]. Replication of EA or H/L
findings included Generation Scotland and CATHGEN
EA samples (n = 7349) and AA included CATHGEN and
HyperGEN samples (n = 760). Among the significantly
identified trans-ethnic DMPs (Bonferroni corrected p-
value and consistent direction of effects), 13 of 78 repli-
cated (Table 1), and among the significantly identified
DMPs in ethnic-specific meta-analyses, 1 of 5 AA DMPs
replicated (cg14871770 at CYP2C9) (Additional file 3:
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Table S3). Despite independent replication in AA,
cg14871770 overlapped with trans-ethnic replicated
DMPs (Fig. 1b). Twelve additional DMPs had replication
(with consistent direction of effects) in trans-ethnic
meta-analyses (Additional file 3: Table S3a). The DMP
cg14871770 overlapped between trans-ethnic and AA
meta-analyses, and the cg17944885 at the ZNF20-
ZNF788P locus was previously described [11]. Several of
the replicated DMPs were expression quantitative trait
methylation loci (eQTM) or cis-meQTL CpGs in whole
blood in FHS and (BIOS QTL) (Table 1) [36–38]. Repli-
cation results for all DMPs are shown in Additional file 3:



















n=  2,879    1,737      812    
       78 DMPs in trans-ethnic, 23 DMPs in AA, 5 in H/L and 5 in EA 
Ethnic-specific meta-analyses Trans-ethnic meta-analyses 
eFORGE DHS analyses 
13 DMPs in trans-ethnic, 1 DMP in AA  




(EA and AA) 

















































Low     High
eGFR
Fig. 1 Overview of trans-ethnic and ethnic-specific CpGs associated with kidney function. a Venn diagram showing trans-ethnic and unique CpGs
across the top 1000 sites for European Americans (EA), African Americans (AA), Hispanic/Latino (H/L), and trans-ethnic groups. b Euler diagram
showing the number of overlapping CpGs (1) between trans-ethnic replicated DMPs (13) and discovery ethnic-specific DMPs for African
Americans -AA- (5). c Study design, consortium information, sample size, and the number of significant DMPs for both trans-ethnic and ethnic-
specific EWAS analyses. Details shown both for discovery (top) and replication analyses (bottom). For these analyses, consortia include the
Women’s Health Initiative (WHI), the Jackson Heart Study (JHS), MESA, HyperGEN, Generation Scotland, and CATHGEN. In addition, we used kidney
DNAm data from the TRANSLATE, TRANSLATE-T, RESPOND, and REPAIR studies for cis-meQTL analyses and Roadmap Epigenomics data
for eFORGE DHS analyses
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Tables S3a (trans-ethnic analyses) and Additional file 3:
Table S3b (ethnic-specific analyses). Forest plots for each
of the replicated DMPs are shown in Additional file 1:
Fig. S3. We also replicated 6 DMPs identified in a prior
publication (DMPs located at genes DAZAP1,
KIAA1549L, TUBGCP4/ZSCAN29, JAZF1, ZNF20-
ZNF788P, LDB2) (Additional file 3: Table S4) [11].
Overlap of eGFR-associated DMPs with genes and
regulatory elements
To understand the regulatory context of our DMPs, we
annotated the 13 replicated significant DMPs with the
closest gene and other information including epigenomic
peaks, tissue-specific gene expression via RNA-seq, and
chromatin interaction annotations. One of our DMPs
(cg11789371) is located in an intron of HSP90AA1, a
gene involved in protecting kidney tissue from inflam-
mation, ischemia, and oxidative damage, and assisting
with cellular repair (Fig. 2) [46]. HSP90 (heat shock pro-
tein 90) has a physiological role in eGFR regulation
through the nitric oxide pathway and is a drug target
candidate for kidney diseases [46]. Indeed, inhibition of
HSP90 has been shown to reduce eGFR in animal
models [46]. DMP cg11789371 overlaps epigenomic an-
notations from the ENCODE consortium including
DNase I hypersensitive sites in kidney cells, among other
cell types. This DMP is a cis-meQTL CpG regulated by
rs11621083, a variant located upstream in an intron of
HSP90AA1. The DMP also forms part of a GeneHancer
interacting site, contacting the promoter of WDR20 and
an alternative promoter of HSP90AA1 which is located
50 kb away. The entire region surrounding this DMP
contains a number of genes expressed in the kidney, sev-
eral of which seem to interact with these two promoters.
Genes from this locus presenting RNA-seq expression in
the kidney include DYNC1H1, MOK, ZNF839, WDR20,
and HSP90AA1. Taken together, annotations for our
DMP cg11789371, which overlaps an intron of
HSP90AA1, a gene associated with eGFR regulation, sug-
gest a potential link between DNA methylation and
eGFR regulation through the nitric oxide pathway.
DMPs for eGFR are enriched for kidney regulatory
function related to kidney development
To further understand the regulatory potential and chro-
matin context of our EWAS findings across different tis-
sues, we performed integrative epigenomics analyses on
data from the Roadmap Epigenomics consortium [34]
us ing the eFORGE framework (ht tps : / /e forge .
altiusinstitute.org/) [32, 33]. We found enrichment for
kidney-specific DNase I hotspots, which has also been de-
scribed in GWAS of eGFR (Fig. 3a, d) [4, 47]. eFORGE
showed consistent enrichment results for kidney-specific
DNase I hotspots when applied to the top EA discovery
probes, showing a corresponding trend with study p-value
(analyses performed using the “EPIC” setting with 1000
repetitions, BY correction). In addition, analysis with
eFORGE-TF uncovered significant enrichment for several
Table 1 Main findings from trans-ethnic EWAS meta-analyses for 13 replicated DMPs







DMP Chr Position (hg38) Gene Effect p 450K EPIC 850 K Effect p Effect p
cg13235761^ 1 203,592,452 − 37.61 4.33E−06 3048 2378 − 25.28 5.08E−05 − 29.81 1.88E−09
cg26099045^* 2 64,064,666 14.82 5.74E−06 3050 2378 11.24 1.01E−04 12.81 3.26E−09
cg04428662^Ω* 4 2,932,461 MFSD10 − 30.84 3.21E−06 3049 2378 − 34.94 3.43E−07 − 32.82 5.51E−12
cg23174201^* 5 151,674,695 SPARC − 35.83 5.10E−06 3050 2378 − 34.87 1.72E−07 − 35.27 4.02E−12
cg17170437 6 44,229,461 SLC29A1 − 47.62 1.96E−06 N/A 2378 − 18.62 1.49E−04 − 24.24 3.80E−08
cg14871770 10 96,658,622 CYP2C9, CYPC19 − 53.12 1.98E−06 N/A 2378 − 25.87 1.70E−04 − 33.36 1.23E−08
cg02157636 11 68,709,367 TESMIN − 53.21 2.15E−06 N/A 2378 − 27.25 1.14E−05 − 33.33 8.58E−10
cg26039141^Ω 11 75,402,116 RPS3 − 39.14 3.40E−06 3050 2378 − 33.42 1.78E−05 − 36.06 2.90E−10
cg22593432^* 13 32,001,768 − 29.91 1.54E−07 3050 2378 − 17.66 1.79E−04 − 22.64 4.61E−10
cg11789371^* 14 102,085,048 HSP90AA1 − 35.40 4.44E−06 3050 2378 − 22.66 3.58E−04 − 27.80 1.41E−08
cg05796561 18 57,128,273 − 45.24 2.96E−06 N/A 2378 − 22.91 1.69E−04 − 29.24 1.41E−08
cg17944885^Ω* 19 12,114,920 ZNF20, ZNF788P − 32.71 1.41E−09 3048 2378 − 16.34 5.67E−07 − 20.72 1.24E−13
cg15787712^ 19 13,837,429 LOC284454, MIR23 − 37.60 6.00E−09 3050 2378 − 28.65 2.06E−05 − 33.30 9.01E−13
p-value for replication < 6.4E−04 (Bonferroni correction for 78 DMPs tested). Four of the 13 DMPs that replicated were non-450K probes (cg17170437, cg14871770,
cg02157636, cg05796561). Results from combined discovery and replication are also shown
GS Generation Scotland, N/A not applicable
^cis-meQTL from the BIOS QTL [36, 37]
ΩExpression quantitative trait methylation (eQTM) data from the BIOS QTL (enrichment p-value <0.01) [36, 37]
*cis-meQTL in the Framingham Heart Study [38]
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transcription factor (TF) motifs (including motifs for
OSR1, OSR2, TBX1, and PAX2). OSR1, OSR2, TBX1, and
PAX2 have all been shown to have roles in kidney devel-
opment (Fig. 3c) [48–50]. To further understand the path-
ways underlying TF motif enrichment, we performed
PANTHER pathway analysis using significant TF motifs
[35]. This analysis uncovered pathways associated with
kidney development, including metanephros development
(8.1 × 10−3), mesonephros development (9.7 × 10−3), and
retinoic acid receptor signaling pathway (6.4 × 10−3) (Add-
itional file 3: Table S5). Overall, these findings suggest that
epigenetic changes related to eGFR are enriched in kidney
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Fig. 2 eGFR-associated differentially methylated position cg11789371. a HSP90AA1 gene browser shot showing (from top to bottom) genome
coordinates, local genes, NHGRI/EBI GWAS catalog SNPs, GTEx gene expression quantified via RNA-seq across different tissues, H3K27ac peaks
across 7 ENCODE cell lines, GeneHancer regulatory elements, Genecards TSSs, GeneHancer chromatin interactions, ENCODE chromatin
accessibility and chromatin interaction tracks, and location for eGFR-associated DMP cg11789371. b Expanded browser shot showing genome
coordinates, local genes, NHGRI/EBI GWAS catalog SNPs, H3K27ac peaks across 7 ENCODE cell lines, and a boxplot indicating DNAm values at
cg11789371 for bottom and top quartiles of eGFR, respectively. These data indicate our DMP overlaps an intron of HSP90AA1, a gene expressed in
kidney tissue, and a DHS from ENCODE, which was detected in kidney tissue. Our DMP is also proximal to an H3K27ac peak, an RNA Polymerase
2 region determined by ENCODE ChIA-PET across several cell lines, and the promoter of HSP90AA1. All browser shots were generated using the
UCSC genome browser (https://genome.ucsc.edu/) on human genome build hg19
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Fig. 3 (See legend on next page.)
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eGFR GWAS variants, meQTL CpGs, and tissue-specific
DNase I hotspots
Previous reports and our analyses confirm that eGFR
GWAS variants are enriched for kidney DNase I hot-
spots (Fig. 3b, Additional file 1: Fig. S4) [4, 47], indicat-
ing that genotypes might function through kidney-
specific regulatory pathways, potentially converging with
identified EWAS DMPs through mechanisms which are
not fully understood. To explore this further, we used
mQTLdb [39] to identify meQTL CpG targets of eGFR-
associated GWAS SNPs obtained from the GWAS cata-
log [44, 51]. These significant meQTL CpGs linked to
GWAS SNPs revealed significant overlap with eGFR
EWAS sites in our study (p < 0.002, Fig. 4a) and pre-
sented significant enrichment for kidney, renal cortex,
and renal pelvis, among other tissues (Fig. 4b, d, Add-
itional file 1: Fig. S5). These results support a model in
which meQTL CpGs linked to eGFR GWAS SNPs over-
lap with EWAS DMPs and tend to localize to kidney
DNase I hotspots, with potential involvement in their
regulatory action (Fig. 4c). To assess these findings in
human kidney tissue, we analyzed meQTL CpGs of
eGFR SNPs localizing to kidney DNase I hotspots. The
meQTL CpGs were identified from DNAm data from
195 normal kidney tissue samples (acquired from elect-
ive nephrectomies—taking the non-cancer affected seg-
ment—or from kidney donors) as reported previously
[40–42]. While kidney meQTL CpGs not associated with
eGFR SNPs (nominal p-value> 0.95) showed no enrich-
ment in kidney DNase I hotspots (Additional file 1: Fig.
S6), the kidney meQTL CpGs with a nominal p-value <
0.05 were enriched in kidney DNase I hotspots (Add-
itional file 1: Fig. S7) for the same GWAS SNPs. These
results support the aforementioned findings using eGFR
SNP-associated meQTL CpGs from mQTLdb [39]. Add-
itionally, we evaluated the overlap between kidney
meQTL CpGs and blood meQTL CpGs (mQTLdb) for
our top EWAS DMPs. The majority (58.3%) of these
kidney meQTL CpGs were also mQTL CpGs in blood.
Discussion
Main findings
This study used trans-ethnic and ethnic-specific analyses
of multi-ethnic cohorts to identify and replicate DMPs
associated with eGFR. Our main findings include repli-
cated DMPs at 13 sites from trans-ethnic analyses and 1
DMP from AA-specific analyses, which may reflect the
larger AA discovery sample compared to other ethnic
groups. All associations were newly identified in this
study, except for the ZNF20-ZNF788P locus, which was
previously described in two separate eGFR EWAS, includ-
ing a population-based cohort and an HIV-infected cohort
[11, 52]. Several DMPs were associated with accessible
chromatin sites in kidney tissue, suggesting a regulatory
role for these sites. Overall, our study identified 12 previ-
ously unreported DMPs that replicated, in addition to 6
previously published DMPs for eGFR among our 93 dis-
covery DMPs [11]. These findings support an association
between DNAm and eGFR, reflecting a convergence of
lifetime influences of genetic effects, lifestyle, behaviors,
and environmental exposures [53–55].
Differences between ethnicities
Our approach of studying multi-ethnic groups identified
DMPs from trans-ethnic and ethnic-specific analyses. This
approach contrasts with a prior study that performed sep-
arate EA and AA analyses with cross-replication across
these groups [11]. Across our two largest ethnic-specific
samples (AA and EA), there was little overlap between
DMPs from discovery analysis, although several discovery
ethnic-identified DMPs did overlap with trans-ethnic find-
ings (Fig. 1a). The DMP cg14871770, which is located be-
tween CYP2C9 and CYP2C19 (cytochrome P450 family 2
subfamily C members 9 and 19), was identified both in
ethnic-specific and trans-ethnic analysis. The closest
GWAS SNP to this DMP is rs4110517, a SNP associated
with blood pressure identified in a multi-ethnic cohort
[56]. CYP2C9 and CYP2C19 encode members of the cyto-
chrome P450 superfamily of enzymes. Cytochrome P450
(See figure on previous page.)
Fig. 3 Tissue-specific integrative analysis indicates potential effect on kidney and relation with eGFR GWAS loci. a eFORGE analysis for top 1000
eGFR CpGs: the x axis indicates tissues/cell type samples used in the analysis; the y axis shows eFORGE enrichment (−log10 p-value) of the CpG
set with DNase I hotspots for a range of tissue samples (significant samples in black). The highest ranked sample set (highest black points) shows
the most significant enrichment is for kidney samples, which are highly ranked for the top 1000 CpGs associated with eGFR. b FORGE2 analysis
for eGFR SNPs from GWAS catalog: the x axis indicates tissues/cell type samples used in the analysis; the y axis shows FORGE2 enrichment
(−log10 p-value) of the SNP set with DNase I hotspots for a range of tissue samples (significant samples in black). The highest ranked sample set
(highest black points) shows the most significant enrichment also is for kidney samples, which are highly ranked for the top 249 SNPs associated
with eGFR (taken from the GWAS catalog, https://www.ebi.ac.uk/gwas/, downloaded 10 April 2020). c TF motif enrichment results for EA probes
driving eFORGE tissue-specific enrichment signal: the x axis indicates TF motifs from TRANSFAC, JASPAR, Taipale/SELEX, and Uniprobe databases;
the y axis shows eFORGE-TF enrichment (−log10 hypergeometric p-value) of the input DMP set with TF motifs overlapping open chromatin sites
for fetal kidney samples. Enrichment values for each TF motif are colored according to BY FDR-corrected q-value. A number of TF motifs involved
in kidney development overlap top EA probes including OSR1, OSR2, TBX1, and PAX2. d Aggregated eFORGE results for EA probes: the x axis
indicates sets of the top ranked DMPs used in the analysis (each set contains 1000 DMPs); the y axis shows eFORGE enrichment (−log10 p-value)
of each of the DMP sets with open chromatin sites for kidney (red) and other tissue samples (gray). The highest ranked probe set (set 1, left)
shows the most significant enrichment for kidney samples, which remain highly ranked for probe sets 2–5, in decreasing order of study p-value
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Fig. 4 (See legend on next page.)
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proteins are monooxygenases that catalyze many reactions
involved in the synthesis of cholesterol, other steroids, and
other lipids, and in drug metabolism. CYP2C19 genotype
is associated with the metabolism of compounds influen-
cing both renal function and hypertension [57]. The rele-
vance of ethnic-specific findings to clinical phenotypes
will need further evaluation in studies with larger samples
inclusive of multiple ethnicities to define improved
DNAm signatures for eGFR that may be unique to one
single ancestry. Our findings suggest reduced utility of
DNAm biomarkers for eGFR in diverse populations if dis-
covery EWAS is performed in a single homogenous
population.
Relevance of HSP90AA1 locus
Among other findings, we report a replicated trans-
ethnic DMP (cg11789371) associated with eGFR that
localizes to an intron of HSP90AA1 (heat shock pro-
tein 90 alpha family class A member 1), a gene
expressed in podocytes, parietal epithelial cells, prox-
imal tubular cells, endothelium, and mesangial cells
in normal kidney tissue, with gene expression in-
creasing in glomerulonephritis and acute kidney in-
jury [46]. The gene product, HSP90, regulates renal
blood flow and eGFR through nitric oxide metabol-
ism and plays a role in protein folding [46]. HSP90
and other heat shock proteins are candidate drug
targets for a variety of kidney diseases [46, 58].
Treatment with radicicol, an inhibitor of HSP90, has
been shown to reduce eGFR in animal models [58].
DMP cg11789371 overlaps an accessible chromatin
region in kidney cells, and a GeneHancer interacting
site contacting the promoters of WDR20 and
HSP90AA1. These and other different annotations
point to a potential regulatory role in kidney tissue
for this eGFR-associated DMP.
Integrative epigenomics and pathway analysis
We detected a significant overlap of eGFR GWAS SNP-
associated meQTL CpGs with kidney DNase I hotspots.
Additionally, our eGFR EWAS DMPs were enriched for
kidney DNase I hotspots. These findings suggest poten-
tial links between the regulatory action of both geno-
types and epigenetic DNAm elements. Importantly,
these integrative epigenomic analyses considered all tis-
sues available instead of only kidney tissue.
While some regions of the methylome show tissue
specificity [59], EWAS have also shown that some
DMPs are shared across different tissues, e.g., the
AHRR locus DNAm patterns in response to smoking
are shared across multiple tissues [60]. Pan-tissue
findings for AHRR suggest similar underlying path-
ways in response to the same environmental stimulus
[60]. Regarding discrepancies in trans-ethnic results,
both genetic and environmental differences could be
at play, potentially interacting with each other. In this
context, our findings of both a kidney-specific DNase
I hotspot and GWAS meQTL enrichment for a whole
blood-based EWAS could be due to both genetic and
environmental origins and warrant further research of
kidney tissue DNAm in association with eGFR. In-
deed, such results raise the intriguing hypothesis that
tissue-specific enrichments observed separately in
GWAS and EWAS might be related by the same gen-
omic variants, thus aiding the integration of both ap-
proaches (Fig. 4a). It is important to highlight that
both whole blood and kidney tissue eQTLs were ob-
tained from individuals of European ethnicity [40–43].
The identification of eGFR DNAm signature-
associated pathways is an important step towards char-
acterizing epigenetic mechanisms for this physiologic
trait and may provide clues to underlying mechanisms
for CKD. Identified DMPs highlight an association with
pathways of kidney development, which can influence
nephron endowment at birth and subsequent CKD risk
[48–50, 61]. Our in silico results were influenced by our
DNAm findings in healthy adult kidney. Therefore, path-
way results from this study support epigenetic effects
during developmental windows with long-term influence
on eGFR, which warrant further investigation.
(See figure on previous page.)
Fig. 4 eGFR EWAS CpGs present a significant overlap with eGFR GWAS-driven meQTL effects. a Histogram of 1000 random background
simulations (249 random SNPs each), for EWAS-meQTL overlap across the ARIES blood meQTL dataset (http://www.mqtldb.org/). Two hundred
forty-nine unique significant SNPs from the eGFR GWAS by Hellwege et al. yield 13 SNP-meQTL-EWAS DMP sites in the Aries cohort (p = 2.0E−03,
empirical test, red dot and arrow), while background SNP sets overlap a mean of 0.912 SNP-meQTL-EWAS sites. b Histogram of 1000 random
background simulations (249 random SNPs each), for meQTL-kidney DNase I hotspot overlap across Roadmap Epigenomics “Kidney” sample
datasets (https://egg2.wustl.edu/roadmap/web_portal/). Two thousand seven hundred thirty-three meQTL targets of 249 unique significant SNPs
from the eGFR GWAS by Hellwege et al. overlap Roadmap kidney DNase I hotspots 519 times (p < 0.001, empirical test, red dot and arrow), while
background SNP sets overlap Roadmap kidney DNase I hotspots a mean of 67.021 times (SD = 24.754). c Schematic showing the association of
eGFR GWAS SNPs with meQTL target CpGs and eGFR EWAS CpGs (both in red text), some of which overlap kidney-specific DNase I hotspots
(shown in blue, arrows indicate statistical association—not genomic contact). For comparison, a representation of a background SNP is shown. d
Results from eFORGE analysis of significant ARIES meQTL CpGs associated with eGFR GWAS SNPs, indicating a higher-than expected overlap with
the kidney, renal cortex, and renal pelvis DNase-seq hotspots (for additional results, see Additional file 1: Fig. S5)
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Limitations
This study is limited by the use of whole blood as
the main tissue (chosen due to its availability). The
discovery datasets included both the Illumina 450K
and the EPIC 850K arrays, which contributed to dif-
ferences in sample sizes and power to detect associa-
tions for some CpGs (Table 1). Post hoc power
analyses suggest adequate power to detect DNAm
differences of the range observed in the study (Add-
itional file 2: Supplementary Methods). The methods
for normalization of the DNAm beta values and
study-specific quality control varied (Additional file 3:
Table S2). However, we applied standardized proto-
cols for data harmonization and statistical analyses
in addition to stringent quality control as part of our
meta-analyses. Our findings showed no heterogeneity
of effects across studies (Additional file 1: Fig. S3),
suggesting that results are robust to study-specific
quality control and normalization procedures. Add-
itionally, our reported DMPs replicated in independ-
ent samples, further validating our results. It is
important to consider whether these DNAm sites as-
sociated with eGFR in blood are also applicable to
effects in kidney tissue. We attempted to answer this
by examining our identified meQTLs in normal kid-
ney tissue in the TRANSLATE study. However, kid-
ney tissue studies still have small sample sizes and
lack ethnic diversity. While epigenomic mapping
consortia such as Roadmap Epigenomics and EN-
CODE have made important steps to increase the
free availability of a wide range of tissue and cell
type-specific datasets, the important issue of includ-
ing additional epigenomics mapping data sets for
other ancestries remains to be addressed. It is im-
portant to highlight that we only observe eFORGE
kidney enrichment for top EA probes. While this
kidney-specific DNase I hotspot enrichment has been
further confirmed by analyzing ranked DMPs in
study p-value order (Fig. 3d), it is not apparent for
DMPs from other ethnicities, or for DMPs for ana-
lysis comprising all ethnicities. DNase-seq datasets
for these samples originate from the Roadmap Epige-
nomics consortium [34], which focused mainly on
tissue samples obtained from EA individuals. With-
out datasets from diverse ethnic groups, it will be
difficult to conclusively study inter-ethnic epige-
nomic variability or perform tissue-specific analyses
for loci from GWAS and EWAS performed on indi-
viduals of non-European origin.
Conclusions
We identified trans-ethnic and ethnic-specific differ-
ential DNAm positions, validated prior published
associations, and showed that several eGFR DMPs
identified in this study replicated in independent sam-
ples. We have also shown that some of the DMPs are
meQTL CpGs, many of which are associated with
pathways relevant for kidney tissue regulation and de-
velopment. Our findings include a DMP at
HSP90AA1, a gene involved in the regulation of eGFR
in kidney tissue. Identification of trans-ethnic and
ethnic-specific DMPs and elucidation of their poten-
tial functional impact are preliminary steps towards
identifying disease-associated epigenetic mechanisms
that are specific to a particular population or shared
across different populations.
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